Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years

Li, Christopher I.; Daling, Janet R.; Tang, Mei Tzu C; Haugen, Kara L.; Porter, Peggy L.; Malone, Kathleen E.

doi:10.1001/jamainternmed.2013.9071

Cited by 117 publications

(134 citation statements)

References 22 publications

Supporting

Mentioning

117

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, these findings were not supported by subsequent observational studies [14][15][16][17][18][19][20][21][22][23], and a mixed treatment comparison meta-analysis [24] also confirmed that no excess incidence of cancer could be imputed to CCBs and other antihypertensive classes. Interestingly, however, a recent population-based case-control study in the three-county Seattle-Puget Sound metropolitan area conducted among women aged 55 to 74 years found that current use of CCBs was associated with higher risks of both ductal and lobular breast cancer, whilst other antihypertensive drug classes were not associated with risk [25].…”

Section: Introductionmentioning

confidence: 98%

The incidence of cancer deaths among hypertensive patients in a large Chinese population: A cohort study

Wong

Tam

Lao

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

Section: Introductionmentioning

confidence: 98%

The incidence of cancer deaths among hypertensive patients in a large Chinese population: A cohort study

Wong

Tam

Lao

et al. 2015

International Journal of Cardiology

View full text Add to dashboard Cite

“…Additionally, many epidemiological studies have supported the antineoplastic effects of β-blocker use [1]. However, some others revealed negative results, adding to the confusion regarding their potential benefit in cancer patients [2,3]. …”

Section: Introductionmentioning

confidence: 99%

β-Blocker Use and Risk of Recurrence in Patients with Early Breast Cancer

Sakellakis¹,

Kostaki

Starakis³

et al. 2014

Chemotherapy

View full text Add to dashboard Cite

Aim: We evaluated whether the concurrent β-blocker use in early breast cancer patients influenced the outcome in terms of preventing tumor recurrence after adjuvant chemotherapy. Methods: We retrospectively reviewed the medical records of 610 patients with breast cancer. Thereafter, we compared overall disease-free survival (DFS) between β-blocker users and nonusers. Results: Those not receiving β-blockers had a relatively longer mean DFS (10.8 vs. 9.7 years), although the difference did not reach statistical significance (p = 0.651). When the survival analysis was adjusted for age, tumor stage, hormone receptor status and HER2 status, the results remained unaltered, suggesting that β-blocker use did not significantly improve overall DFS (HR, 0.849; 95% CI, 0.537-1.343; p = 0.485). Conclusion: Our findings failed to confirm previous results indicating a potential antitumor effect of β-blockers.

show abstract

“…For instance, left ventricular hypertrophy should not be dismissed as a minor condition. Recognizing left ventricular hypertrophy is relevant to oncologists because arterial hypertension is highly prevalent among cancer patients and is associated with increased cardiovascular risk [19,20,21,22]. In this study, the presence of left ventricular hypertrophy was associated with NT-proBNP >100 pg/ml.…”

Section: Discussionmentioning

confidence: 74%

Limitations of N-Terminal Pro-B-Type Natriuretic Peptide in the Diagnosis of Heart Disease among Cancer Patients Who Present with Cardiac or Pulmonary Symptoms

Wieshammer

Dreyhaupt²,

Müller

et al. 2016

Oncology

View full text Add to dashboard Cite

Objectives: Recognizing heart disease is relevant to oncologists because cancer patients are at an increased risk of cardiac mortality due to shared risk factors and the adverse effects of cancer therapy. This study assessed the extent to which the measurement of N-terminal pro-B-type natriuretic peptide (NT-proBNP) aids in the diagnosis of heart disease in addition to a history of coronary artery disease and the presence of atrial fibrillation (composite test). The NT- proBNP cutoff value was 100 pg/ml. Methods: A series of 583 consecutive cancer patients (68.4 ± 11.0 years) who were referred because of cardiac or pulmonary symptoms prospectively underwent a diagnostic work-up. Heart disease was diagnosed if at least one of the following conditions was present: (a) history of coronary artery disease, (b) atrial fibrillation, (c) impaired left ventricular systolic function, (d) significant valvular disease, (e) pulmonary hypertension, or (f) left ventricular hypertrophy. Results: Except for (a), all 6 conditions were associated with NT-proBNP >100 pg/ml. The sensitivity/specificity values of the composite test were 0.92/0.50 for any heart disease. Several extracardiac covariates were associated with NT-proBNP >100 pg/ml, which contributed to the low test specificity. Conclusions: The low specificity of NT-proBNP limits its value for the diagnosis of heart disease in cancer patients.

show abstract

Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years

Cited by 117 publications

References 22 publications

The incidence of cancer deaths among hypertensive patients in a large Chinese population: A cohort study

The incidence of cancer deaths among hypertensive patients in a large Chinese population: A cohort study

β-Blocker Use and Risk of Recurrence in Patients with Early Breast Cancer

Limitations of N-Terminal Pro-B-Type Natriuretic Peptide in the Diagnosis of Heart Disease among Cancer Patients Who Present with Cardiac or Pulmonary Symptoms

Contact Info

Product

Resources

About